Antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023.
A(H1N1)pdm09
A(H3N2)
Antibody
Antigenic drift
Immunity gap
Influenza
Serology
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
09
10
2023
accepted:
26
02
2024
medline:
8
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
epublish
Résumé
Non-pharmaceutical interventions implemented during the COVID-19 pandemic resulted in a marked reduction in influenza infections globally. The absence of influenza has raised concerns of waning immunity, and potentially more severe influenza seasons after the pandemic. To evaluate immunity towards influenza post-COVID-19 pandemic we have assessed influenza A epidemics in Norway from October 2016 to June 2023 and measured antibodies against circulating strains of influenza A(H1N1)pdm09 and A(H3N2) in different age groups by hemagglutination inhibition (HAI) assays in a total of 3364 serum samples collected in 2019, 2021, 2022 and 2023. Influenza epidemics in Norway from October 2016 until June 2023 were predominately influenza As, with a mixture of A(H1N1)pdm09 and A(H3N2) subtype predominance. We did not observe higher numbers of infections during the influenza epidemics following the COVID-19 pandemic than in pre-COVID-19 seasons. Frequencies of protective HAI titers against A(H1N1)pdm09 and A(H3N2) viruses were reduced in sera collected in 2021 and 2022, compared to sera collected in 2019. The reduction could, however, largely be explained by antigenic drift of new virus strains, as protective HAI titers remained stable against the same strain from one season to the next. However, we observed the development of an immunity gap in the youngest children during the pandemic which resulted in a prominent reduction in HAI titers against A(H1N1)pdm09 in 2021 and 2022. The immunity gap was partially closed in sera collected in 2023 following the A(H1N1)pdm09-dominated influenza seasons of 2022/2023. During the 2022/2023 epidemic, drift variants of A(H1N1)pdm09 belonging to the 5a.2a.1 clade emerged, and pre-season HAI titers were significantly lower against this clade compared to the ancestral 5a.2 clade. The observed reduction in protective antibodies against A(H1N1)pdm09 and A(H3N2) viruses post COVID-19 is best explained by antigenic drift of emerging viruses, and not waning of antibody responses in the general population. However, the absence of influenza during the pandemic resulted in an immunity gap in the youngest children. While this immunity gap was partially closed following the 2022/2023 influenza season, children with elevated risk of severe infection should be prioritized for vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Non-pharmaceutical interventions implemented during the COVID-19 pandemic resulted in a marked reduction in influenza infections globally. The absence of influenza has raised concerns of waning immunity, and potentially more severe influenza seasons after the pandemic.
METHODS
METHODS
To evaluate immunity towards influenza post-COVID-19 pandemic we have assessed influenza A epidemics in Norway from October 2016 to June 2023 and measured antibodies against circulating strains of influenza A(H1N1)pdm09 and A(H3N2) in different age groups by hemagglutination inhibition (HAI) assays in a total of 3364 serum samples collected in 2019, 2021, 2022 and 2023.
RESULTS
RESULTS
Influenza epidemics in Norway from October 2016 until June 2023 were predominately influenza As, with a mixture of A(H1N1)pdm09 and A(H3N2) subtype predominance. We did not observe higher numbers of infections during the influenza epidemics following the COVID-19 pandemic than in pre-COVID-19 seasons. Frequencies of protective HAI titers against A(H1N1)pdm09 and A(H3N2) viruses were reduced in sera collected in 2021 and 2022, compared to sera collected in 2019. The reduction could, however, largely be explained by antigenic drift of new virus strains, as protective HAI titers remained stable against the same strain from one season to the next. However, we observed the development of an immunity gap in the youngest children during the pandemic which resulted in a prominent reduction in HAI titers against A(H1N1)pdm09 in 2021 and 2022. The immunity gap was partially closed in sera collected in 2023 following the A(H1N1)pdm09-dominated influenza seasons of 2022/2023. During the 2022/2023 epidemic, drift variants of A(H1N1)pdm09 belonging to the 5a.2a.1 clade emerged, and pre-season HAI titers were significantly lower against this clade compared to the ancestral 5a.2 clade.
CONCLUSION
CONCLUSIONS
The observed reduction in protective antibodies against A(H1N1)pdm09 and A(H3N2) viruses post COVID-19 is best explained by antigenic drift of emerging viruses, and not waning of antibody responses in the general population. However, the absence of influenza during the pandemic resulted in an immunity gap in the youngest children. While this immunity gap was partially closed following the 2022/2023 influenza season, children with elevated risk of severe infection should be prioritized for vaccination.
Identifiants
pubmed: 38448981
doi: 10.1186/s12985-024-02326-w
pii: 10.1186/s12985-024-02326-w
pmc: PMC10916265
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2024. The Author(s).
Références
Emborg HD, Carnahan A, Bragstad K, Trebbien R, Brytting M, Hungnes O, et al. Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden. Euro Surveill. 2021;26(22):2001160.
doi: 10.2807/1560-7917.ES.2021.26.22.2001160
pubmed: 34085632
pmcid: 8176675
Saunes IS, Vrangbaek K, Byrkjeflot H, Jervelund SS, Birk HO, Tynkkynen LK, et al. Nordic responses to Covid-19: governance and policy measures in the early phases of the pandemic. Health Policy. 2022;126(5):418–26.
doi: 10.1016/j.healthpol.2021.08.011
pubmed: 34629202
Folkehelseinstituttet, Risiko ved covid-19-epidemien, influensa og RSV-infeksjon i Norge. (2022)
Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. 2021;148(3):e2021052089.
doi: 10.1542/peds.2021-052089
pubmed: 34108234
Weinberger Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T. Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill. 2021;26(29):2100706.
doi: 10.2807/1560-7917.ES.2021.26.29.2100706
pubmed: 34296678
pmcid: 8299746
Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021;73(9):e2829–30.
doi: 10.1093/cid/ciaa1906
pubmed: 33594407
Chen B, Zhu Z, Li Q, He D. Resurgence of different influenza types in China and the US in 2021. Math Biosci Eng. 2023;20(4):6327–33.
doi: 10.3934/mbe.2023273
pubmed: 37161109
Sominina A, Danilenko D, Komissarov A, Karpova L, Pisareva M, Fadeev A, et al. Resurgence of influenza circulation in the russian federation during the delta and omicron COVID-19 era. Viruses. 2022;14(9):1909.
doi: 10.3390/v14091909
pubmed: 36146716
pmcid: 9506591
Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383–97.
doi: 10.1038/s41577-019-0143-6
pubmed: 30837674
Fisman DN, Savage R, Gubbay J, Achonu C, Akwar H, Farrell DJ, et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med. 2009;361(20):2000–1.
doi: 10.1056/NEJMc0907256
pubmed: 19907052
Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20):1945–52.
doi: 10.1056/NEJMoa0906453
pubmed: 19745214
Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill. 2010;15(31):19633.
doi: 10.2807/ese.15.31.19633-en
pubmed: 20738992
Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455(7212):532–6.
doi: 10.1038/nature07231
pubmed: 18716625
pmcid: 2848880
Ray GT, Lewis N, Klein NP, Daley MF, Wang SV, Kulldorff M, et al. Intraseason waning of influenza vaccine effectiveness. Clin Infect Dis. 2019;68(10):1623–30.
doi: 10.1093/cid/ciy770
pubmed: 30204855
Ferdinands JM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011–12 through 2014–15. Clin Infect Dis. 2017;64(5):544–50.
pubmed: 28039340
Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, Mc IC. Do antibody responses to the influenza vaccine persist year-round in the elderly?+ A systematic review and meta-analysis. Vaccine. 2017;35(2):212–21.
doi: 10.1016/j.vaccine.2016.11.013
pubmed: 27939013
Mordant FL, Price OH, Rudraraju R, Slavin MA, Marshall C, Worth LJ, et al. Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months. Influenza Other Respir Viruses. 2023;17(1): e13072.
doi: 10.1111/irv.13072
pubmed: 36451293
Haaheim LR. Surveillance of the antibody status to current influenza strains in the Norwegian population. 1: Method of serum sampling and evaluation of the A/USSR/77 (H1N1) impact in various age groups in 1978. NIPH Ann. 1979;2(2):45–54.
pubmed: 548838
Haaheim LR. Surveillance of the antibody status to current influenza strains in the Norwegian population. 2: antibodies to the A/USSR/90/77 (H1N1) virus in various age groups after the second epidemic wave. NIPH Ann. 1980;3(1):49–56.
pubmed: 7454125
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–77.
pubmed: 4509641
Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69–75.
doi: 10.1093/oxfordjournals.bmb.a071545
pubmed: 367490
Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother. 2013;9(2):405–8.
doi: 10.4161/hv.22908
pubmed: 23291930
pmcid: 3859764
Tunheim G, Ro GOI, Chopra A, Aase A, Kran AB, Vaage JT, et al., Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021. Influenza Other Respir Viruses, (2022)
Population count. 2023, Statistics Norway: www.ssb.no
Schulze M, Nitsche A, Schweiger B, Biere B. Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS ONE. 2010;5(4): e9966.
doi: 10.1371/journal.pone.0009966
pubmed: 20376359
pmcid: 2848602
Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83(19):10309–13.
doi: 10.1128/JVI.01109-09
pubmed: 19605485
pmcid: 2748056
Tamura K, Stecher G, Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. Mol Biol Evol. 2021;38(7):3022–7.
doi: 10.1093/molbev/msab120
pubmed: 33892491
pmcid: 8233496
Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25.
pubmed: 3447015
Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A. 2004;101(30):11030–5.
doi: 10.1073/pnas.0404206101
pubmed: 15258291
pmcid: 491989
Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13):30494.
doi: 10.2807/1560-7917.ES.2017.22.13.30494
pubmed: 28382917
pmcid: 5388101
World Health O and Network WHOGIS, Manual for the laboratory diagnosis and virological surveillance of influenza. 2011, Geneva: World Health Organization. 139 p
Waalen K, Kilander A, Dudman SG, Ramos-Ocao R, Hungnes O. Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill. 2012;17(19):20170.
doi: 10.2807/ese.17.19.20170-en
pubmed: 22607964
Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995;96(3 Pt 2):600–3.
doi: 10.1542/peds.96.3.600
pubmed: 7659485
John McCauley RD, Yi Pu Lin, Ruth Harvey, Monica Galiano, Zheng Xiang, Lynne Whittaker, Chandrika Halai, Karen Cross, Aine Rattigan, Burcu Ermetal, Alice Lilley, Mian Dai, Michael Bennett, Saira Hussain, Report prepared for the WHO annual consultation on the composition of influenza vaccines for the Southern Hemisphere 2020. 2019, Worldwide Influenza Centre, The Francis Crick Institute.
Nicola Lewis RD, Ruth Harvey, Monica Galiano, Zheng Xiang, Lynne Whittaker, Christine Carr, Burcu Ermetal, Karen Cross, Karen Cross, Alice Lilley, Michael Bennett, Chandrika Halai, Chandrika Halai, Lorin Adams, Report prepared for the WHO annual consultation on the composition of influenza vaccines for the Northern Hemisphere 2023–2024. 2023, Worldwide Influenza Centre, The Francis Crick Institute
Recommended composition of influenza virus vaccines for use in the 2023–2024 northern hemisphere influenza season. 2023: www.who.int
Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. Pediatric infectious disease group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51(5):418–23.
doi: 10.1016/j.idnow.2021.05.004
pubmed: 33991720
pmcid: 8114587
Trieu MC, Jul-Larsen A, Saevik M, Madsen A, Nostbakken JK, Zhou F, et al. Antibody responses to influenza A/H1N1pdm09 virus after pandemic and seasonal influenza vaccination in healthcare workers: a 5-year follow-up study. Clin Infect Dis. 2019;68(3):382–92.
doi: 10.1093/cid/ciy487
pubmed: 29893797
Galson JD, Truck J, Kelly DF, van der Most R. Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. Sci Rep. 2016;6:37229.
doi: 10.1038/srep37229
pubmed: 27849037
pmcid: 5110968
Tenforde MW, Kondor RJG, Chung JR, Zimmerman RK, Nowalk MP, Jackson ML, et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States-2019-2020. Clin Infect Dis. 2021;73(11):e4244–50.
doi: 10.1093/cid/ciaa1884
pubmed: 33367650
Werninghaus IC, Hinke DM, Fossum E, Bogen B and Braathen R, Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza. Mol Ther, 2023.
Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013;207(6):974–81.
doi: 10.1093/infdis/jis935
pubmed: 23307936
pmcid: 3633450
Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis. 2015;212(8):1191–9.
doi: 10.1093/infdis/jiv195
pubmed: 25858957